<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02294370</url>
  </required_header>
  <id_info>
    <org_study_id>Botnia012014</org_study_id>
    <nct_id>NCT02294370</nct_id>
  </id_info>
  <brief_title>Variation of Glucose Values at Early Stages of Diabetes - Continuous Glucose Monitoring</brief_title>
  <official_title>Glucose Excursions at Early Stages of Diabetes, MOSAIC Prospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Folkhälsan Researech Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Padova</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Universidad Politecnica de Madrid</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pavia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fondazione Salvatore Maugeri</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asociación Española Para el Desarrollo de la Epidemiologia Clínica</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Soluciones Tecnologias para la Salud y el Bienestar SA</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Technical University of Athens</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Folkhälsan Researech Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study aims at improving the prediction of type 2 diabetes among high-risk individuals by&#xD;
      examining glucose excursion patterns in subjects with impaired glucose tolerance. In&#xD;
      addition, this study will show whether the currently used diagnostic test could be replaced&#xD;
      by an easier and less expensive method.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes is a chronic disease of glucose metabolism leading to various disabling&#xD;
      conditions. The onset of type 2 diabetes is a gradual shift from normal to abnormal, giving&#xD;
      rarely noticeable symptoms at its early stages or even in later stages when damage has&#xD;
      already been caused. Due to the gradual onset, the diagnosis is often delayed, and as much as&#xD;
      half of the asymptomatic patients remain undetected. The diagnostic criteria for diabetes are&#xD;
      based on artificial boundaries reflecting the risk of complications related to diabetes. The&#xD;
      golden standard of diagnosis of diabetes is a 2 hours oral glucose tolerance test, which is&#xD;
      both time consuming and costly. This study aims at improving the prediction of type 2&#xD;
      diabetes among high-risk individuals by examining glucose excursion patterns in subjects with&#xD;
      impaired glucose tolerance. In addition, this study will show whether the currently used&#xD;
      diagnostic test could be replaced by an easier and less expensive method.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2013</start_date>
  <completion_date type="Actual">June 2015</completion_date>
  <primary_completion_date type="Actual">June 2015</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>glucose levels in tissue fluid</measure>
    <time_frame>continuous monitoring for 1 week</time_frame>
    <description>continuous glucose monitoring system</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>capillary glucose</measure>
    <time_frame>4 times a day for 1 week</time_frame>
    <description>for the calibration of the continuous glucose monitoring system</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">62</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>subjects at the early stages of diabetes</arm_group_label>
    <description>Subjects at the early stages of diabetes, individuals with impaired glucose tolerance (IGT, 2h plasma glucose during oral glucose tolerance test &gt;7.8-11.1 mmol/l (n=50) or with type 2 diabetes (fasting plasma glucose &gt; 7.0 mmol/l and/or 2h plasma glucose &gt; 11.1 mmol/l on two occasions, or both criteria fulfilled in same oral glucose tolerance test while not pregnant, n=50) with short duration (&lt;3 years)</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      serum, plasma, urine&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Individuals with impaired glucose tolerance (2h plasma glucose during oral glucose&#xD;
        tolerance test &gt;7.8-11.1 mmol/l, n=50) or with type 2 diabetes (fasting plasma glucose &gt;&#xD;
        7.0 mmol/l and/or 2h plasma glucose &gt; 11.1 mmol/l on two occasions, or both criteria&#xD;
        fulfilled in the same oral glucose tolerance test while not pregnant, n=50) with short&#xD;
        duration (&lt;3 years); 40 from Padova University Hospital, 60 from the Botnia Study or the&#xD;
        PPP-Botnia Study in Finland. The Botnia Study and the PPP-Botnia Study are population based&#xD;
        studies investigating type 2 diabetes in western Finland.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals with impaired glucose tolerance (2h plasma glucose during oral glucose&#xD;
             tolerance test &gt;7.8-11.1 mmol/l, n=50) or with type 2 diabetes (fasting plasma glucose&#xD;
             &gt; 7.0 mmol/l and/or 2h plasma glucose &gt; 11.1 mmol/l on two occasions, or both criteria&#xD;
             fulfilled in the same oral glucose tolerance test while not pregnant, n=50) with short&#xD;
             duration (&lt;3 years); 40 from Padova University Hospital, 60 from the Botnia Study or&#xD;
             the PPP (Prevalence, Prediction, Prevention)-Botnia Study in Finland.&#xD;
&#xD;
          -  Age 40-75 years&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Medication with: insulin, glucagon-like peptide-1 (GLP-1)-analogues, sulphonylureas,&#xD;
             oral corticosteroids, thyreostatic agents or thyroid hormone,&#xD;
             luteinizing-hormone-releasing hormone (LHRH) analogues&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known changes in retinal fundus photographs&#xD;
&#xD;
          -  Known, microalbuminuria&#xD;
&#xD;
          -  HbA1c &gt;8%&#xD;
&#xD;
          -  Fasting plasma glucose &gt;10 mmol/l&#xD;
&#xD;
          -  Medication with metformin, glitazones, gliptins (or acarbose) is allowed but gliptins&#xD;
             and acarbose need to be stopped 2 days before testing and during the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tiinamaija Tuomi, MD,lecturer</last_name>
    <role>Principal Investigator</role>
    <affiliation>Folkhalsan</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Folkhälsan Research Center</name>
      <address>
        <city>Helsinki</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Finland</country>
  </location_countries>
  <reference>
    <citation>Soliman A, DeSanctis V, Yassin M, Elalaily R, Eldarsy NE. Continuous glucose monitoring system and new era of early diagnosis of diabetes in high risk groups. Indian J Endocrinol Metab. 2014 May;18(3):274-82. doi: 10.4103/2230-8210.131130. Review.</citation>
    <PMID>24944918</PMID>
  </reference>
  <reference>
    <citation>Wang C, Lv L, Yang Y, Chen D, Liu G, Chen L, Song Y, He L, Li X, Tian H, Jia W, Ran X. Glucose fluctuations in subjects with normal glucose tolerance, impaired glucose regulation and newly diagnosed type 2 diabetes mellitus. Clin Endocrinol (Oxf). 2012 Jun;76(6):810-5. doi: 10.1111/j.1365-2265.2011.04205.x.</citation>
    <PMID>21854404</PMID>
  </reference>
  <verification_date>March 2016</verification_date>
  <study_first_submitted>November 17, 2014</study_first_submitted>
  <study_first_submitted_qc>November 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 19, 2014</study_first_posted>
  <last_update_submitted>March 11, 2016</last_update_submitted>
  <last_update_submitted_qc>March 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>type 2 diabetes</keyword>
  <keyword>continuous glucose monitoring</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

